Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11407432 | 0.76 | XDH (0.30) | — | |
| SCHEMBL458710 | 0.76 | IMPDH2 (0.33) | — | |
| SCHEMBL8994063 | 0.76 | XDH (0.34) | KDM4E | |
| SCHEMBL3407215 | 0.76 | ALDH1A1 (0.39) | NPC1KDM4E | |
| SCHEMBL15265720 | 0.72 | — | — | |
| SCHEMBL175905 | 0.72 | — | — | |
| SCHEMBL14128749 | 0.71 | NPC1 (0.41) | NPC1KDM4E | |
| SCHEMBL10824003 | 0.71 | KDM4E (0.42) | NPC1KDM4E | |
| SCHEMBL29376868 | 0.71 | — | — | |
| SCHEMBL10630213 | 0.71 | ALDH1A1 (0.48) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| CN-110642788-A | Preparation method of 5-bromo-2-substituted pyrimidine compound | 广州大学 | 2020-01-03 | — | — | CN | disclosed |
| US-10323017-B2 | Antioxidants and methods to maximize performance | Alma Mater Studiorum—Universita di Bologna (IT) | 2019-06-18 | — | — | US | disclosed |
| US-20180022729-A1 | Antioxidants and Methods to Maximize Performance | UNIVERSITY OF OTTAWA (CA) | 2018-01-25 | — | — | US | disclosed |
| WO-2016123717-A1 | ANTIOXIDANTS AND METHODS TO MAXIMIZE PERFORMANCE | UNIVERSITY OF OTTAWA (CA) | 2016-08-11 | — | — | WO | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1363705-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-4898968-A | INSECTICIDES, MITICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-06 | — | — | US | disclosed |
| US-4760143-A | Contining pyrimidine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-26 | — | — | US | disclosed |
| US-4661488-A | Pyrimidine substituted-2,2-dimethylcyclopropane carboxylates useful for combating insect and acarine pests at a locus | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-04-28 | — | — | US | disclosed |
| EP-0162538-A2 | Cyclopropane derivates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | NPC1 1381/4885KDM4E 1154/4885 |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | NPC1 1827/4885KDM4E 1380/4885 |
| US-20180022729-A1 | Antioxidants and Methods to Maximize Performance | CAT, AOX1, SOD1 | NPC1 3715/4885KDM4E 2237/4885 |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | NPC1 2355/4885KDM4E 3001/4885 |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | NPC1 2766/4885KDM4E 758/4885 |
| US-10323017-B2 | Antioxidants and methods to maximize performance | CAT, AOX1, SOD1 | NPC1 3715/4885KDM4E 2237/4885 |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | NPC1 1784/4885KDM4E 696/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | NPC1 629/4885KDM4E 1105/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | NPC1 1966/4885KDM4E 761/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | NPC1 713/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.